Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 334

1.

European experience and risk factor analysis of donor cell-derived leukaemias/MDS following haematopoietic cell transplantation.

Engel N, Rovo A, Badoglio M, Labopin M, Basak GW, Beguin Y, Guyotat D, Ljungman P, Nagler A, Schattenberg A, Schroeder T, Schroyens W, Tischer J, Socie G, Kolb HJ, Tichelli A, Salooja N, Duarte RF; Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation.

Leukemia. 2018 Jul 26. doi: 10.1038/s41375-018-0218-6. [Epub ahead of print]

PMID:
30050122
2.

Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft-versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation.

Trento C, Bernardo ME, Nagler A, Kuçi S, Bornhäuser M, Köhl U, Strunk D, Galleu A, Sanchez-Guijo F, Gaipa G, Introna M, Bukauskas A, Le Blanc K, Apperley J, Roelofs H, Van Campenhout A, Beguin Y, Kuball J, Lazzari L, Avanzini MA, Fibbe W, Chabannon C, Bonini C, Dazzi F.

Biol Blood Marrow Transplant. 2018 Jul 20. pii: S1083-8791(18)30402-6. doi: 10.1016/j.bbmt.2018.07.015. [Epub ahead of print]

PMID:
30031938
3.

Outcomes of Advanced Hodgkin Lymphoma after Umbilical Cord Blood Transplantation: A Eurocord and EBMT Lymphoma and Cellular Therapy & Immunobiology Working Party Study.

Paviglianiti A, Maio KT, Rocha V, Gehlkopf E, Milpied N, Esquirol A, Chevallier P, Blaise D, Gac AC, Leblond V, Cahn JY, Abecasis M, Zuckerman T, Schouten H, Gurman G, Rubio MT, Beguin Y, Corral LL, Nagler A, Snowden JA, Koc Y, Mordini N, Bonifazi F, Volt F, Kenzey C, Robinson SP, Montoto S, Gluckman E, Ruggeri A.

Biol Blood Marrow Transplant. 2018 Jul 19. pii: S1083-8791(18)30407-5. doi: 10.1016/j.bbmt.2018.07.019. [Epub ahead of print]

PMID:
30031070
4.

Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT.

McLornan DP, Szydlo R, Robin M, van Biezen A, Koster L, Blok HJP, Van Lint MT, Finke J, Vitek A, Carlson K, Griskevicius L, Holler E, Itälä-Remes M, Schaap M, Socié G, Bay JO, Beguin Y, Bruno B, Cornelissen JJ, Gedde-Dahl T, Ljungman P, Rubio MT, Yakoub-Agha I, Klyuchnikov E, Olavarria E, Chalandon Y, Kröger N.

Br J Haematol. 2018 May 29. doi: 10.1111/bjh.15407. [Epub ahead of print]

PMID:
29808926
5.

Infusion of bone marrow derived multipotent mesenchymal stromal cells for the treatment of steroid-refractory acute graft-versus-host disease: a multicenter prospective study.

Servais S, Baron F, Lechanteur C, Seidel L, Selleslag D, Maertens J, Baudoux E, Zachee P, Van Gelder M, Noens L, Kerre T, Lewalle P, Schroyens W, Ory A, Beguin Y.

Oncotarget. 2018 Apr 17;9(29):20590-20604. doi: 10.18632/oncotarget.25020. eCollection 2018 Apr 17.

6.

Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity in multiple myeloma bone disease.

Muller J, Bolomsky A, Dubois S, Duray E, Stangelberger K, Plougonven E, Lejeune M, Léonard A, Marty C, Hempel U, Baron F, Beguin Y, Cohen-Solal M, Ludwig H, Heusschen R, Caers J.

Haematologica. 2018 Aug;103(8):1359-1368. doi: 10.3324/haematol.2017.185397. Epub 2018 May 10.

7.

A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis.

Laureys G, Willekens B, Vanopdenbosch L, Deryck O, Selleslag D, D'Haeseleer M, De Becker A, Dubois B, Dierickx D, Perrotta G, De Wilde V, van Pesch V, Straetmans N, Dive D, Beguin Y, Van Wijmeersch B, Theunissen K, Kerre T, Van de Velde A.

Acta Neurol Belg. 2018 Jun;118(2):161-168. doi: 10.1007/s13760-018-0905-0. Epub 2018 Mar 13.

PMID:
29536270
8.

Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines.

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee.

Ann Oncol. 2018 Feb 20. doi: 10.1093/annonc/mdx758. [Epub ahead of print] No abstract available.

PMID:
29471514
9.

Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: a survey from the acute leukemia working party of EBMT.

Roth-Guepin G, Canaani J, Ruggeri A, Labopin M, Finke J, Cornelissen JJ, Delage J, Stuhler G, Rovira M, Potter M, Stadler M, Veelken H, Cahn JY, Collin M, Beguin Y, Giebel S, Nagler A, Mohty M.

Oncotarget. 2017 Dec 4;8(68):112972-112979. doi: 10.18632/oncotarget.22934. eCollection 2017 Dec 22.

10.

Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin's lymphoma undergoing allogeneic haematopoietic cell transplantation-a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy.

Gauthier J, Poiré X, Gac AC, Leclerc M, Guillaume T, Chalandon Y, Nguyen S, Forcade E, Régny C, Bay JO, Bazarbachi A, Rohrlich PS, Huynh A, Farhi J, Marchand T, Malfuson JV, Pilorge S, Labussière-Wallet H, Renard C, Fornecker LM, Detrait M, Duléry R, Delage J, Ménard AL, Charbonnier A, Nelken B, Jubert C, Suarez F, de la Tour RP, Beguin Y, Schoemans H, Blaise D, Yakoub-Agha I.

Bone Marrow Transplant. 2018 Apr;53(4):400-409. doi: 10.1038/s41409-017-0018-z. Epub 2018 Jan 12.

PMID:
29330405
11.

Disease and treatment characteristics of polycythemia vera patients in Belgium: Results from a scientific survey.

Devos T, Beguin Y, Noens L, Van Eygen K, Zachée P, Mineur P, Knoops L, Doyen C, Theunissen K, Benghiat FS, Reusens M, Pluymers W.

Eur J Haematol. 2018 Apr;100(4):361-366. doi: 10.1111/ejh.13022. Epub 2018 Feb 7.

PMID:
29285836
12.

Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.

Decroocq J, Itzykson R, Vigouroux S, Michallet M, Yakoub-Agha I, Huynh A, Beckerich F, Suarez F, Chevallier P, Nguyen-Quoc S, Ledoux MP, Clement L, Hicheri Y, Guillerm G, Cornillon J, Contentin N, Carre M, Maillard N, Mercier M, Mohty M, Beguin Y, Bourhis JH, Charbonnier A, Dauriac C, Bay JO, Blaise D, Deconinck E, Jubert C, Raus N, Peffault de Latour R, Dhedin N.

Am J Hematol. 2018 Mar;93(3):416-423. doi: 10.1002/ajh.25004. Epub 2018 Jan 8.

PMID:
29226497
13.

[Management of the chronic graft versus host disease: Guidelines from the Francophone society of bone marrow transplantation and cellular therapies (SFGM-TC)].

Magro L, Forcade E, Giraud C, Granata A, Parquet N, Rohrlich PS, Terriou L, Yakoub-Agha I, Beguin Y.

Bull Cancer. 2017 Dec;104(12S):S145-S168. doi: 10.1016/j.bulcan.2017.10.023. Epub 2017 Nov 24. Review. French.

14.

A First Report on [18F]FPRGD2 PET/CT Imaging in Multiple Myeloma.

Withofs N, Cousin F, De Prijck B, Bonnet C, Hustinx R, Gambhir SS, Beguin Y, Caers J.

Contrast Media Mol Imaging. 2017 Jul 27;2017:6162845. doi: 10.1155/2017/6162845. eCollection 2017.

15.

Antimicrobial Resistance in Gram-Negative Rods Causing Bacteremia in Hematopoietic Stem Cell Transplant Recipients: Intercontinental Prospective Study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group.

Averbuch D, Tridello G, Hoek J, Mikulska M, Akan H, Yanez San Segundo L, Pabst T, Özçelik T, Klyasova G, Donnini I, Wu D, Gülbas Z, Zuckerman T, Botelho de Sousa A, Beguin Y, Xhaard A, Bachy E, Ljungman P, de la Camara R, Rascon J, Ruiz Camps I, Vitek A, Patriarca F, Cudillo L, Vrhovac R, Shaw PJ, Wolfs T, O'Brien T, Avni B, Silling G, Al Sabty F, Graphakos S, Sankelo M, Sengeloev H, Pillai S, Matthes S, Melanthiou F, Iacobelli S, Styczynski J, Engelhard D, Cesaro S.

Clin Infect Dis. 2017 Nov 13;65(11):1819-1828. doi: 10.1093/cid/cix646.

16.

Inefficacy of autologous bone marrow concentrate in stage three osteonecrosis: a randomized controlled double-blind trial.

Hauzeur JP, De Maertelaer V, Baudoux E, Malaise M, Beguin Y, Gangji V.

Int Orthop. 2018 Jul;42(7):1429-1435. doi: 10.1007/s00264-017-3650-8. Epub 2017 Oct 7.

PMID:
28988340
17.

High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation-lymphoma working party.

Akhtar S, Montoto S, Boumendil A, Finel H, Masszi T, Jindra P, Nemet D, Fuhrmann S, Beguin Y, Castagna L, Ferrara F, Capria S, Malladi R, Moraleda JM, Bloor A, Ghesquières H, Meissner J, Sureda A, Dreger P.

Am J Hematol. 2018 Jan;93(1):40-46. doi: 10.1002/ajh.24927. Epub 2017 Nov 9.

18.

Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects.

Ehx G, Fransolet G, de Leval L, D'Hondt S, Lucas S, Hannon M, Delens L, Dubois S, Drion P, Beguin Y, Humblet-Baron S, Baron F.

Oncoimmunology. 2017 Apr 12;6(5):e1314425. doi: 10.1080/2162402X.2017.1314425. eCollection 2017.

19.

Reconstitution of adaptive immunity after umbilical cord blood transplantation: impact on infectious complications.

Servais S, Hannon M, Peffault de Latour R, Socie G, Beguin Y.

Stem Cell Investig. 2017 May 25;4:40. doi: 10.21037/sci.2017.05.03. eCollection 2017. Review.

20.

Molecular mechanisms, current management and next generation therapy in myeloma bone disease.

Heusschen R, Muller J, Duray E, Withofs N, Bolomsky A, Baron F, Beguin Y, Menu E, Ludwig H, Caers J.

Leuk Lymphoma. 2018 Jan;59(1):14-28. doi: 10.1080/10428194.2017.1323272. Epub 2017 Jun 2. Review.

PMID:
28573897
21.

Salvage use of allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders subcommittee of the European Group for Blood and Marrow Transplant Chronic Malignancies Working Party.

Sobh M, Michallet M, Dubois V, Iacobelli S, Koster L, Van Biezen A, Fegueux N, Tabrizi R, Finke J, El-Cheikh J, Schipperus M, Meijer E, von dem Borne P, Petersen E, Russell N, Tholouli E, Passweg J, Garban F, Maertens J, Chevalier P, Maillard N, Volin L, Francois S, Lioure B, Beguin Y, Gluckman E, Ruggeri A, Garderet L, Kröger N.

Haematologica. 2017 Jul;102(7):e271-e274. doi: 10.3324/haematol.2017.165399. Epub 2017 Apr 20. No abstract available.

22.

[Anemia in patients with severe chronic obstructive pulmonary disease, a comorbity more common than previously thought].

Pirotte M, Guiot J, Beguin Y, Louis R.

Rev Med Liege. 2016 Nov;71(11):488-494. French.

23.

Cognitive compensatory processes of older, clinically fit patients with hematologic malignancies undergoing chemotherapy: A longitudinal cohort study.

Libert Y, Borghgraef C, Beguin Y, Delvaux N, Devos M, Doyen C, Dubruille S, Etienne AM, Liénard A, Merckaert I, Reynaert C, Slachmuylder JL, Straetmans N, Van Den Neste E, Bron D, Razavi D.

Psychooncology. 2017 Dec;26(12):2086-2093. doi: 10.1002/pon.4424. Epub 2017 May 16.

24.

Infusion of mesenchymal stromal cells after deceased liver transplantation: A phase I-II, open-label, clinical study.

Detry O, Vandermeulen M, Delbouille MH, Somja J, Bletard N, Briquet A, Lechanteur C, Giet O, Baudoux E, Hannon M, Baron F, Beguin Y.

J Hepatol. 2017 Jul;67(1):47-55. doi: 10.1016/j.jhep.2017.03.001. Epub 2017 Mar 9.

25.

Outcome after failure of allogeneic hematopoietic stem cell transplantation in children with acute leukemia: a study by the société Francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC).

Roux C, Tifratene K, Socié G, Galambrun C, Bertrand Y, Rialland F, Jubert C, Pochon C, Paillard C, Sirvent A, Nelken B, Vannier JP, Freycon C, Beguin Y, Raus N, Yakoub-Agha I, Mohty M, Dalle JH, Michel G, Pradier C, Peffault de Latour R, Rohrlich PS.

Bone Marrow Transplant. 2017 May;52(5):678-682. doi: 10.1038/bmt.2016.360. Epub 2017 Jan 23.

26.

Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy.

Gauthier J, Castagna L, Garnier F, Guillaume T, Socié G, Maury S, Maillard N, Tabrizi R, Marchand T, Malfuson J, Gac A, Gyan E, Mercier M, Béguin Y, Delage J, Turlure P, Marçais A, Nguyen S, Dulery R, Bay J, Huynh A, Daguindau E, Cornillon J, Régny C, Michallet M, Peffault de Latour R, Yakoub-Agha I, Blaise D.

Bone Marrow Transplant. 2017 May;52(5):689-696. doi: 10.1038/bmt.2016.349. Epub 2017 Jan 9.

PMID:
28067872
27.

The clinical relevance of imatinib plasma trough concentrations in chronic myeloid leukemia. A Belgian study.

Van Obbergh F, Knoops L, Devos T, Beguin Y, Graux C, Benghiat F, Kargar-Samani K, Bauwens D, Efira A, Dubois C, Springael C, Montfort L, Connerotte T, Capron A, Delannoy A, Wallemacq P.

Clin Biochem. 2017 May;50(7-8):452-454. doi: 10.1016/j.clinbiochem.2016.12.006. Epub 2016 Dec 22.

28.

Limited Impact of Imatinib in a Murine Model of Sclerodermatous Chronic Graft-versus-Host Disease.

Belle L, Fransolet G, Somja J, Binsfeld M, Delvenne P, Drion P, Hannon M, Beguin Y, Ehx G, Baron F.

PLoS One. 2016 Dec 12;11(12):e0167997. doi: 10.1371/journal.pone.0167997. eCollection 2016.

29.

Review article: mesenchymal stromal cell therapy for inflammatory bowel diseases.

Grégoire C, Lechanteur C, Briquet A, Baudoux É, Baron F, Louis E, Beguin Y.

Aliment Pharmacol Ther. 2017 Jan;45(2):205-221. doi: 10.1111/apt.13864. Epub 2016 Nov 22. Review.

30.

[Assessment and management of post-transplant iron overload: Guidelines of the Francophone Society of Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Jaspers A, Bouhya S, Belaiche S, Chevallier P, Hermet E, Hospital-Gustems C, Michallet M, Rialland F, Samsonova O, Sirvent A, Yakoub-Agha I, Rohrlich PS, Beguin Y.

Bull Cancer. 2016 Nov;103(11S):S255-S266. doi: 10.1016/j.bulcan.2016.09.003. Epub 2016 Nov 11. French.

31.

Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT.

Heidenreich S, Ziagkos D, de Wreede LC, van Biezen A, Finke J, Platzbecker U, Niederwieser D, Einsele H, Bethge W, Schleuning M, Beelen DW, Tischer J, Nagler A, Glass B, Maertens J, Yáñez L, Beguin Y, Sill H, Scheid C, Stelljes M, Ganser A, Zachée P, Selleslag D, de Witte T, Robin M, Kröger N.

Biol Blood Marrow Transplant. 2017 Jan;23(1):44-52. doi: 10.1016/j.bbmt.2016.09.027. Epub 2016 Oct 5.

32.

Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma.

Binsfeld M, Muller J, Lamour V, De Veirman K, De Raeve H, Bellahcène A, Van Valckenborgh E, Baron F, Beguin Y, Caers J, Heusschen R.

Oncotarget. 2016 Jun 21;7(25):37931-37943. doi: 10.18632/oncotarget.9270.

33.

Genomic studies of multiple myeloma reveal an association between X chromosome alterations and genomic profile complexity.

Sticca T, Caberg JH, Wenric S, Poulet C, Herens C, Jamar M, Josse C, El Guendi S, Max S, Beguin Y, Gothot A, Caers J, Bours V.

Genes Chromosomes Cancer. 2017 Jan;56(1):18-27. doi: 10.1002/gcc.22397. Epub 2016 Aug 18.

34.

Azacytidine mitigates experimental sclerodermic chronic graft-versus-host disease.

Fransolet G, Ehx G, Somja J, Delens L, Hannon M, Muller J, Dubois S, Drion P, Caers J, Humblet-Baron S, Delvenne P, Beguin Y, Conteduca G, Baron F.

J Hematol Oncol. 2016 Jul 4;9(1):53. doi: 10.1186/s13045-016-0281-2.

35.

Clinical-scale expansion of mesenchymal stromal cells: a large banking experience.

Lechanteur C, Briquet A, Giet O, Delloye O, Baudoux E, Beguin Y.

J Transl Med. 2016 May 20;14(1):145. doi: 10.1186/s12967-016-0892-y.

36.

Novel approaches for preventing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Servais S, Beguin Y, Delens L, Ehx G, Fransolet G, Hannon M, Willems E, Humblet-Baron S, Belle L, Baron F.

Expert Opin Investig Drugs. 2016 Aug;25(8):957-72. doi: 10.1080/13543784.2016.1182498. Epub 2016 May 9. Review.

37.

SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma.

Heusschen R, Muller J, Binsfeld M, Marty C, Plougonven E, Dubois S, Mahli N, Moermans K, Carmeliet G, Léonard A, Baron F, Beguin Y, Menu E, Cohen-Solal M, Caers J.

Oncotarget. 2016 May 24;7(21):30712-29. doi: 10.18632/oncotarget.8750.

38.

Yellow nail syndrome after allogeneic haematopoietic stem cell transplantation in two patients with multiple myeloma.

Gregoire C, Guiot J, Vertenoeil G, Willems É, Hafraoui K, Corhay JL, Louis R, Beguin Y.

Acta Clin Belg. 2016 Dec;71(6):428-430. Epub 2016 Feb 6.

39.

Allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning regimen for elderly patients (60 years and older) with hematologic malignancies using unrelated donors: a retrospective study from the French society for stem cell transplantation (SFGM-TC).

El Cheikh J, Sfumato P, Sobh M, Fegueux N, Mohty M, Vigouroux S, Beguin Y, Yakoub-Agha I, Socié G, Cornillon J, Mercier M, Bay JO, Blaise D, Michallet M, Peffault de Latour R.

Haematologica. 2016 Jun;101(6):e262-5. doi: 10.3324/haematol.2015.139345. Epub 2016 Mar 18. No abstract available.

40.

Prophylactic donor lymphocyte infusion in patients with high-risk acute myeloid leukemia: ready for prime time?

Baron F, Beguin Y.

Bone Marrow Transplant. 2016 May;51(5):640-2. doi: 10.1038/bmt.2016.38. Epub 2016 Mar 14. No abstract available.

41.

Factors associated with self-perceived burden to the primary caregiver in older patients with hematologic malignancies: an exploratory study.

Libert Y, Borghgraef C, Beguin Y, Delvaux N, Devos M, Doyen C, Dubruille S, Etienne AM, Liénard A, Merckaert I, Reynaert C, Slachmuylder JL, Straetmans N, Van Den Neste E, Bron D, Razavi D.

Psychooncology. 2017 Jan;26(1):118-124. doi: 10.1002/pon.4108. Epub 2016 Mar 4.

42.

The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective.

Caers J, Fernández de Larrea C, Leleu X, Heusschen R, Zojer N, Decaux O, Kastritis E, Minnema M, Jurczyszyn A, Beguin Y, Wäsch R, Palumbo A, Dimopoulos M, Mateos MV, Ludwig H, Engelhardt M.

Oncologist. 2016 Mar;21(3):333-42. doi: 10.1634/theoncologist.2015-0303. Epub 2016 Feb 26. Review.

43.

Validation of a multicolor staining to monitor phosphoSTAT5 levels in regulatory T-cell subsets.

Ehx G, Hannon M, Beguin Y, Humblet-Baron S, Baron F.

Oncotarget. 2015 Dec 22;6(41):43255-66. doi: 10.18632/oncotarget.6486.

44.

Effect of immune modulation in relapsed peripheral T-cell lymphomas after post-allogeneic stem cell transplantation: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

Mamez AC, Lévy V, Chevallier P, Blaise D, Vigouroux S, Xhaard A, Fegueux N, Contentin N, Beguin Y, Ifrah N, Bulabois CE, Suarez F, Yakoub-Agha I, Turlure P, Deconink E, Lamy T, Cahn JY, Huynh A, Maury S, Fornecker LM, Ouzegdouh M, Bay JO, Guillerm G, Maillard N, Michallet M, Malfuson JV, Bourhis JH, Rialland F, Oumedaly R, Jubert C, Leblond V, Boubaya M, Mohty M, Nguyen S.

Bone Marrow Transplant. 2016 Mar;51(3):358-64. doi: 10.1038/bmt.2015.280. Epub 2015 Nov 23.

45.

[Current management of marginal zone lymphomas].

Bonnet C, Lejeune M, Van Kemseke C, Bron D, Beguin Y.

Rev Med Suisse. 2015 Aug 26;11(483):1549-56. French.

PMID:
26502581
46.

Allogeneic haematopoietic stem cell transplantation for mitochondrial neurogastrointestinal encephalomyopathy.

Halter JP, Michael W, Schüpbach M, Mandel H, Casali C, Orchard K, Collin M, Valcarcel D, Rovelli A, Filosto M, Dotti MT, Marotta G, Pintos G, Barba P, Accarino A, Ferra C, Illa I, Beguin Y, Bakker JA, Boelens JJ, de Coo IF, Fay K, Sue CM, Nachbaur D, Zoller H, Sobreira C, Pinto Simoes B, Hammans SR, Savage D, Martí R, Chinnery PF, Elhasid R, Gratwohl A, Hirano M.

Brain. 2015 Oct;138(Pt 10):2847-58. doi: 10.1093/brain/awv226. Epub 2015 Aug 10.

47.

Mesenchymal Stromal Cell Therapy in Ischemia/Reperfusion Injury.

Rowart P, Erpicum P, Detry O, Weekers L, Grégoire C, Lechanteur C, Briquet A, Beguin Y, Krzesinski JM, Jouret F.

J Immunol Res. 2015;2015:602597. doi: 10.1155/2015/602597. Epub 2015 Jul 15. Review.

48.

Management of Myelodysplastic Syndrome Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation: A Study by the French Society of Bone Marrow Transplantation and Cell Therapies.

Guièze R, Damaj G, Pereira B, Robin M, Chevallier P, Michallet M, Vigouroux S, Beguin Y, Blaise D, El Cheikh J, Roos-Weil D, Thiebaut A, Rohrlich PS, Huynh A, Cornillon J, Contentin N, Suarez F, Lioure B, Mohty M, Maillard N, Clement L, François S, Guillerm G, Yakoub-Agha I.

Biol Blood Marrow Transplant. 2016 Feb;22(2):240-247. doi: 10.1016/j.bbmt.2015.07.037. Epub 2015 Aug 6.

49.

Erythropoietin therapy after allogeneic hematopoietic cell transplantation has no impact on long-term survival.

Jaspers A, Baron F, Servais S, Lejeune M, Willems É, Seidel L, Hafraoui K, Bonnet C, Beguin Y.

Am J Hematol. 2015 Sep;90(9):E197-9. doi: 10.1002/ajh.24100. Epub 2015 Aug 14. No abstract available.

50.

Impact of Pre-Transplant Anti-T Cell Globulin (ATG) on Immune Recovery after Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation.

Servais S, Menten-Dedoyart C, Beguin Y, Seidel L, Gothot A, Daulne C, Willems E, Delens L, Humblet-Baron S, Hannon M, Baron F.

PLoS One. 2015 Jun 22;10(6):e0130026. doi: 10.1371/journal.pone.0130026. eCollection 2015.

Supplemental Content

Loading ...
Support Center